Steven Cohen's HAE Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 853,379 shares of Haemonetics Corporation (HAE) worth $68.4 M, representing 0.08% of the portfolio. First purchased in 2016-Q3, this long-term strategic position has been held for 32 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in HAE, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2020, adding 849,744 shares. Largest reduction occurred in Q4 2020, reducing 1.39 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +810,328 | Add 1882.25% | 853,379 | $80.15 |
| Q3 2025 | -395,273 | Reduce 90.18% | 43,051 | $48.74 |
| Q2 2025 | +17,394 | Add 4.13% | 438,324 | $74.61 |
| Q1 2025 | +420,930 | New Buy | 420,930 | $63.55 |
| Q3 2024 | -219,024 | Sold Out | 0 | $0.00 |
| Q2 2024 | +140,324 | Add 178.30% | 219,024 | $82.73 |
| Q1 2024 | -7,383 | Reduce 8.58% | 78,700 | $85.35 |
| Q4 2023 | +86,083 | New Buy | 86,083 | $85.51 |
| Q2 2023 | -29,700 | Sold Out | 0 | $0.00 |
| Q1 2023 | -344,146 | Reduce 92.06% | 29,700 | $82.75 |
| Q4 2022 | -183,693 | Reduce 32.95% | 373,846 | $78.65 |
| Q3 2022 | +148,642 | Add 36.35% | 557,539 | $74.03 |
| Q2 2022 | +408,897 | New Buy | 408,897 | $65.18 |
| Q4 2021 | -266,100 | Sold Out | 0 | $0.00 |
| Q3 2021 | +175,500 | Add 193.71% | 266,100 | $70.59 |
| Q2 2021 | -99,100 | Reduce 52.24% | 90,600 | $66.64 |
| Q1 2021 | -90,732 | Reduce 32.35% | 189,700 | $111.01 |
| Q4 2020 | -1.39 M | Reduce 83.17% | 280,432 | $118.75 |
| Q3 2020 | +849,744 | Add 104.03% | 1.67 M | $87.25 |
| Q2 2020 | +361,442 | Add 79.37% | 816,825 | $89.56 |
| Q1 2020 | +455,383 | New Buy | 455,383 | $99.66 |
| Q3 2019 | -339,961 | Sold Out | 0 | $0.00 |
| Q2 2019 | -519,449 | Reduce 60.44% | 339,961 | $120.34 |
| Q1 2019 | +55,648 | Add 6.92% | 859,410 | $87.48 |
| Q4 2018 | +796,862 | Add 11548.72% | 803,762 | $100.05 |
| Q3 2018 | +6,900 | New Buy | 6,900 | $114.64 |
| Q2 2018 | -61,189 | Sold Out | 0 | $0.00 |
| Q1 2018 | -416,011 | Reduce 87.18% | 61,189 | $73.17 |
| Q4 2017 | +477,200 | New Buy | 477,200 | $58.08 |
| Q1 2017 | -82,058 | Sold Out | 0 | $0.00 |
| Q4 2016 | -603,742 | Reduce 88.03% | 82,058 | $40.20 |
| Q3 2016 | +685,800 | New Buy | 685,800 | $36.21 |
Steven Cohen's Haemonetics Corporation Investment FAQs
Steven Cohen first purchased Haemonetics Corporation (HAE) in Q3 2016, acquiring 685,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Haemonetics Corporation (HAE) for 32 quarters since Q3 2016.
Steven Cohen's largest addition to Haemonetics Corporation (HAE) was in Q3 2020, adding 1,666,569 shares worth $145.41 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 853,379 shares of Haemonetics Corporation (HAE), valued at approximately $68.4 M.
As of the Q4 2025 filing, Haemonetics Corporation (HAE) represents approximately 0.08% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Haemonetics Corporation (HAE) was 1,666,569 shares, as reported at the end of Q3 2020.